The evolving role of biologics in the treatment of pediatric psoriasis.
This article will provide a summary of the cumulative pediatric safety and efficacy data for the anti-tumor necrosis factor-alpha (TNF-α) agents and interleukin (IL)-12 and IL-23 (IL12/23) pathway inhibitor and suggestions for a rational clinical approach to their use in children with psoriasis.
PMID: 23508772 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Luu M, Cordoro KM Tags: Skin Therapy Lett Source Type: research
More News: Children | Dermatology | Laboratory Medicine | Pediatrics | Psoriasis | Skin | Toxicology